期刊名称：JOURNAL OF ONCOLOGY PHARMACY PRACTICE
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
eISSN: 1477092X | ISSN: 10781552
DESCRIPTION
Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer and is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP).
Publishing pertinent case reports and consensus guidelines that drive clinical practice, this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research.
As the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP), the Journal of Oncology Pharmacy Practice contains regular updates on ISOPP activities, as well as practical issues relating to oncology pharmacy and worker safety.
This journal is a member of the Committee on Publication Ethics (COPE).
AIMS AND SCOPE
Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer and is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP).
Publishing pertinent case reports and consensus guidelines that drive clinical practice, this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research.
As the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP), the Journal of Oncology Pharmacy Practice contains regular updates on ISOPP activities, as well as practical issues relating to oncology pharmacy and worker safety.
Articles include:
- Comprehensive and critical reviews of drug use in cancer patient care
- Institutional policies on medication use, with outcome indicators
- Reports of innovative services, policies, and outcome measure tools
- Brief comments on articles published in the journal or other information of interest
- Opinions about controversial therapeutic areas and comments about practice-related issues
- An indispensable pharmaceutical journal to assist your practice.
ABSTRACTING / INDEXING
Academic Search Premier
Biosciences Citation Index
Chemical Abstracts Service (CAS)
Cumulative Index to Nursing and Allied Health Literature CINAHL
EMBASE/Excerpta Medica
Elsevier BIOBASE/Current Awareness in Biological Sciences
Index Medicus
Index Medicus (Ceased 2004)
International Pharmaceutical Abstracts
MEDLINE
Science Citation Index Expanded
Scopus
Instructions to Authors
SUBMISSION GUIDELINES
- Article types
- Editorial Policies
2.1 Peer review policy
2.2 Authorship
2.3 Acknowledgments
2.4 Funding
2.5 Declaration of conflicting interests
2.6 Research ethics and patient consent
2.7 Clinical Trials
2.8 Reporting Guidelines
2.9 Data
- Publishing Policies
3.1 Publication Ethics
3.2 Contributor's publishing agreement
3.3 Open Access and author archiving
3.4 Permissions
- Preparing your manuscript
4.1 Word processing formats
4.2 Artwork, figures and other graphics
4.3 Supplementary material
4.4 Journal layout
4.5 Reference style
4.6 English language editing services
- Submitting your manuscript
5.1 How to submit your manuscript
5.2 Title, keywords and abstracts
5.3 Corresponding author contact details
- On acceptance and publication
6.1 SAGE Production
6.2 Access to your published article
6.3 Online First publication
- Further Information
This Journal is a member of the Committee on Publication Ethics
This Journal recommends that authors follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (ICMJE)
There are no fees payable to submit or publish in this journal.
Please read the guidelines below then visit the Journal’s submission site http://mc.manuscriptcentral.com/jopp to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Journal of Oncology Pharmacy Practice will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
The Journal of Oncology Pharmacy Practice (JOPP) is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer and is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP).
JOPP publishes cancer drug therapy and cancer disease management review articles, research papers, pertinent case reports, editorials, and consensus guidelines that drive clinical practice.
As the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP), the Journal of Oncology Pharmacy Practice contains articles about practical issues relating to oncology pharmacy including papers about safe handling of cytotoxic agents.
Back to top
1. Article types
Manuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another publication. However, the journal will consider manuscripts previously presented as limited posters and abstracts during conferences or in supplements.
The journal publishes review articles, original research papers, practice guidelines, practice issues, case reports, letters to the editor, and editorials/commentaries.
Review Articles. Comprehensive and critical reviews of drug use in cancer patient care. For medication review articles please include introduction, pharmacology, pharmacokinetics/ pharmacodynamics, therapeutic use, clinical use controversies, product description (cost, special preparation and/or administrative considerations), and perspectives on use (summary paragraph including how this drug fits into current practice). For disease and supportive care management reviews include introduction, epidemiology, etiology, pathophysiology, patient presentation, common staging systems used (for malignancy treatment reviews), treatment (include surgery, radiation, but focus on drug therapy aspects), and summary. It is highly desirable to include a flow-diagram treatment algorithm to summarize disease management.
Original Research Articles. Articles should include a clear statement of purpose; a brief historical review; and a description of the methods, procedures, subjects used, statistical analysis, results, discussion, and conclusions (with clinical implications). For research involving human subjects, a statement must be included to assure that the principles set forth in the the Declaration of Helsinki 1975, revised Hong Kong 1989, were followed or that approval from a local or regional committee on human investigation was obtained. A statement must also be included attesting that informed consent was obtained from each subject or the subject's guardian.
Practice Guidelines. Institutional policies on medication use with outcome indicators.
Practice Issues. Reports of innovative services, policies, or outcome measure tools.
Case Series/Reports. Include an introduction justifying the case report, the case description, and discussion.
Letters to the Editor. Brief comments on articles published in the Journal or other information of interest to our readers.
Editorials/ Commentaries. Expression of opinions about controversial therapeutic areas or comments about practice-related issues are encouraged.
Back to top
2. Editorial policies
2.1 Peer review policy
The journal's policy is to obtain at least two independent reviews of each article. It operates a double-blind reviewing policy in which the reviewer’s name is always concealed from the submitting author; authors may choose to reveal their name but the journal otherwise leaves the article anonymous. Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations.
All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.
As part of the submission process you will be asked to provide the names of X peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
- The reviewer should have no prior knowledge of your submission
- The reviewer should not have recently collaborated with any of the authors
- Reviewer nominees from the same institution as any of the authors are not permitted
Please note that the Editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.
2.2 Authorship
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published.
Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
2.3 Acknowledgements
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
2.3.1 Writing Assistance
Individuals who provided writing assistance, e.g. from a specialist communciations company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.
It is not necessary to disclose use of language polishing services.
Please supply any personal acknowledgements separately to the main text to facilitate anonymous peer review.
2.4 Funding
Journal of Oncology Pharmacy Practice requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
2.5 Declaration of conflicting interests
It is the policy of Journal of Oncology Pharmacy Practice to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations here
2.6 Research ethics and patient consent
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted.
2.7 Clinical trials
Journal of Oncology Pharmacy Practice conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
2.8 Reporting guidelines
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart as a cited figure, and a completed CONSORT checklist as a supplementary file.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives
2.9 Data
SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.
Journal of Oncology Pharmacy Practice requests all authors submitting any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at jovie.mcmillan@sagepub.co.uk
Back to top
3. Publishing policies
3.1 Publication ethics
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway
3.1.1 Plagiarism
Journal of Oncology Pharmacy Practice and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies; or taking appropriate legal action.
3.2 Contributor's publishing agreement
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
3.3 Open Access and author archiving
Journal of Oncology Pharmacy Practice offers optional open access publishing via the SAGE Choice programme. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.
3.4 Permissions
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway
Back to top
4. Preparing your manuscript
4.1 Word processing formats
Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. LaTeX files are also accepted. The text should be double-spaced throughout and with a minimum of 3cm for left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
4.2 Artwork, figures and other graphics
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines
Figures supplied in colour will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the costs from SAGE after receipt of your accepted article.
Images should be supplied as bitmap based files (i.e. with .tiff or .jpeg extension) with a resolution of at least 300 dpi (dots per inch). Line art should be supplied as vector-based, separate .eps files (not as .tiff files, and not only inserted in the Word or pdf file), with a resolution of 600 dpi. Images should be clear, legible, in focus, free of pixilation and not too light or dark.
If, together with your accepted article, you submit usable colour figures, these figures will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the possible costs from SAGE after receipt of your accepted article.
In text: tables and figures are either inserted as part of a sentence, for example table 1 or in parentheses for example (figure 1). Each table should carry a descriptive heading. Each figure should be submitted electronically.
4.3 Supplementary material
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article. Please contact the Editor (bgoldspiel@verizon.net) in the first instance. For more information please refer to our guidelines on submitting supplementary files, which can be found within our Manuscript Submission Guidelines page.
4.4 Journal layout
Journal of Oncology Pharmacy Practice conforms to the SAGE house style. Click here to review guidelines on SAGE UK House Style.
4.5 Reference style
Journal of Oncology Pharmacy Practice adheres to the SAGE Vancouver reference style. Click here to review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.
If you use EndNote to manage references, you can download the SAGE Vancouver output file here
4.6 English language editing services
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Back to top
5. Submitting your manuscript
5.1 How to submit your manuscript
Before submitting your manuscript, please ensure you carefully read and adhere to all the guidelines and instructions to authors provided below. Manuscripts not conforming to these guidelines may be returned.
Journal of Oncology Pharmacy Practice is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/jopp to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
If you would like to discuss your paper prior to submission contact the Editor:
bgoldspiel@verizon.net
If you seek advice on the submission process please contact the Publishing Editor: jovie.mcmillan@sagepub.co.uk
5.2 Title, keywords and abstracts
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online
5.3 Corresponding author contact details
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
Back to top
6. On acceptance and publication
6.1 SAGE Production
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.
6.2 Access to your published article
SAGE provides authors with online access to their final article.
6.3 Online First publication
Online First allows final revision articles (completed articles in queue for assignment to an upcoming issue) to be published online prior to their inclusion in a final journal issue which significantly reduces the lead time between submission and publication. For more information please visit our Online First Fact Sheet
Back to top
7. Further Information
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Publishing Editor as follows:
Jovie Mcmillan
Publishing Editor
SAGE Publications
1 Oliver's Yard
55 City Road
London
EC1Y 1SP
jovie.mcmillan@sagepub.co.uk
+44 (0)20 7336 1244
Back to top
Editorial Board
Editorial Board
| Larry Broadfield |
Cancer Care Nova Scotia, Canada |
| John E Brown |
Kingston University, UK |
| Yaakov Cass |
Ministry of Health, Israel |
| Carole Chambers |
Alberta Health Services Pharmacy, Canada |
| Thomas Connor |
National Institure for Occupational Safety and Health, Cincinnati, USA |
| Sylvie Crauste-Manciet |
University of Paris V - Rene Descartes, France |
| Mario De Lemos |
BC Cancer Agency, Vancouver, Canada |
| George Dranitsaris |
Ontario Cancer Institute (OCI), Princess Margaret Hospital, Ontario, Canada |
| Peter Gilbar |
Toowoomba Health Service, Australia |
| R. Donald Harvey |
Emory University, Atlanta, GA, USA |
| Lisa Holle |
University of Connecticut School of Pharmacy, Storrs, CT, USA |
| Sabine Kaestner |
University Hospital Malmo, Sweden |
| Dan Mellor |
Peter MacCallum Cancer Centre, Australia |
| Shereen Nabhani |
Kingston University, UK |
| Lynne Nakashima |
BC Cancer Agency, Vancouver Cancer Centre, Canada |
| Kamal Sabra |
St Jame's Hospital, Republic of Ireland |
| Manit Saeteaw |
Ubon Ratchathani University, Ubon Ratchathani, Thailand |
| Rowena Schwartz |
McKesson Specialty Health, USA |
| Judith Smith |
The University of Texas Health Science Center at Houston, USA |
| Andrew Stanley |
The City Hospital NHS Trust, UK |
| Lindsay Stansfield |
Denver Health, Denver, CO, USA |
| Nicola Stoner |
Cancer Research UK, Oxford, UK |
| Steve Stricker |
Takeda Oncology, Florence, KY, USA |
| Richard Wastnage |
Faulding Pharmaceuticals, Leamington Spa, UK |
| Lorraine Webster |
Mayne Pharma, Victoria, Australia |
| Gunter Wiedemann |
Oberschwabenklinik, Ravensburg, Germany |
| Keary Zhou |
The Chinese University of Hong Kong, Shatin, N.T., Hong Kong |
| 
